-transparent.png){kind=logo}
Postanoxic myoclonus was first accepted as being related to a dysfunction of the ventrolateral thalamic nucleus. Several stereotaxic studies have invalidated this hypothesis. The neurochemical approach, in particular the measure of 5-hydroxyindolacetic acid in the cerebrospinal fluid, has opened new theoretical and therapeutic possibilities involving serotoninergic pathways. A typical case is presented who improved markedly under a combined therapy with 5-hydroxytryptophan and a decarboxylase inhibitor. A review of the pathogenesis and therapeutic approach to postanoxic myoclonus is presented.
Related Publications
E Beretta, and
F Regli, and
G de Crousaz, and
A J Steck
March 1977,
Acta neurologica Scandinavica,
E Beretta, and
F Regli, and
G de Crousaz, and
A J Steck
November 1961,
Journal of applied physiology,
E Beretta, and
F Regli, and
G de Crousaz, and
A J Steck
August 2018,
PM & R : the journal of injury, function, and rehabilitation,
E Beretta, and
F Regli, and
G de Crousaz, and
A J Steck
January 1986,
Advances in neurology,
E Beretta, and
F Regli, and
G de Crousaz, and
A J Steck
January 1969,
Folia medica Cracoviensia,
E Beretta, and
F Regli, and
G de Crousaz, and
A J Steck
February 1979,
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
E Beretta, and
F Regli, and
G de Crousaz, and
A J Steck
April 2003,
Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society,
E Beretta, and
F Regli, and
G de Crousaz, and
A J Steck
July 2005,
Clinical EEG and neuroscience,
E Beretta, and
F Regli, and
G de Crousaz, and
A J Steck
February 1975,
Neurology,
E Beretta, and
F Regli, and
G de Crousaz, and
A J Steck
January 1971,
Revue neurologique,
